This review highlights the vital role of intermolecular electron transfer in photodynamic therapy, emphasizing its potential in developing effective type I photosensitizers.
Hypoxia is an intrinsic characteristic within tumors or infected tissues, which poses a significant barrier to effective photodynamic therapy (PDT). Type I PDT is a promising complement or alternative to conventional Type II PDT owing to its reduced or absent reliance on molecular oxygen. Type I photosensitizers (PSs) are essential to Type I PDT, which undergoes photoinduced electron transfer with biological substrates to produce cytotoxic radical species (O 2 − •, •OH) for the targeted destruction of pathological tissues. However, the limited mechanistic understanding of photoinduced electron transfer makes the rational design of Type I PSs a great challenge. Encouragingly, compelling evidence reveals that intermolecular electron transfer ( Inter ET) is not an obscure mechanism, but rather the predominant photochemical engine driving Type I PDT. This Perspective reviews the evolution and challenges of Inter ET in Type I PDT, with a particular focus on semiempirical design principles for Inter ET‐based Type I PSs. Finally, it is concluded with an outlook on future opportunities and remaining challenges in the development of next‐generation Type I PSs.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: